# Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

> **NCT03755193** · PHASE2 · RECRUITING · sponsor: **Shinshu University** · enrollment: 90 (estimated)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"
- **DRUG:** Bisphosphonates and ELD "Edirol®Tablet 0.75ug"
- **DRUG:** ELD "Edirol®Tablet 0.75ug"

## Key facts

- **NCT ID:** NCT03755193
- **Lead sponsor:** Shinshu University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-11-24
- **Primary completion:** 2024-11-23
- **Final completion:** 2026-11-23
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755193, "Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03755193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*